Press release
Odense, Denmark – March 06, 2026 – Inverna Therapeutics is pleased to announce that Chief Executive Officer, Poul Sørensen, has been invited to present at the RNA Leaders Europe 2026 Congress, taking place from March 17 to 19, 2026, at the Austria Center in Vienna.
Presentation details:
- Date: Wednesday, March 18, 2026
- Time: 11:30 AM
“With their focus on shaping the future of RNA innovation, RNA Leaders Europe is an ideal platform to showcase our progress, and we appreciate the invitation,” said Poul Sørensen, CEO of Inverna Therapeutics. “Precision medicines are at the center of therapeutic innovation, and our ability to target pseudo-exons with high specificity and minimal off-target effects positions us to address significant unmet medical needs.”
About Inverna Therapeutics
Inverna Therapeutics is a Danish biotech company, founded in 2024 emerging from Southern Danish University in Odense, nurtured by Argobio Studio, a launch platform for Europe’s best medicinal science. With our proprietary drug discovery platform, we’re dedicated to developing transformative RNA therapeutics based on precision RNA splicing modulation. Our unique technology allows us to design, test, and develop highly specific activators of pseudo-exons in disease-relevant target RNA. Today, we are pursuing breakthroughs in neurological disorders such as Parkinson’s disease, somatic repeat expansion diseases, and Huntington’s disease, knowing that the approach can extend to other organ systems and diseases.
Contact :
- Poul Sørensen, CEO of Inverna Therapeutics
- psorensen@invernatx.com
